Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1976 3
1977 8
1978 3
1979 2
1980 1
1981 1
1982 10
1983 3
1984 2
1985 2
1986 5
1987 2
1988 3
1989 5
1990 4
1991 10
1992 20
1993 19
1994 20
1995 21
1996 32
1997 30
1998 37
1999 50
2000 56
2001 44
2002 58
2003 107
2004 121
2005 158
2006 184
2007 184
2008 196
2009 199
2010 205
2011 227
2012 266
2013 269
2014 263
2015 270
2016 244
2017 259
2018 249
2019 260
2020 256
2021 249
2022 235
2023 230
2024 105

Text availability

Article attribute

Article type

Publication date

Search Results

4,642 results

Results by year

Filters applied: . Clear all
Page 1
The use of memantine in neuropsychiatric disorders: An overview.
Lu S, Nasrallah HA. Lu S, et al. Ann Clin Psychiatry. 2018 Aug;30(3):234-248. Ann Clin Psychiatry. 2018. PMID: 30028898 Review.
For schizophrenia, memantine has been reported to be consistently effective for negative symptoms only. The manic phase of bipolar disorder also appears to benefit from memantine. The depressive phase of bipolar disorder and major depressive disorder did not respond …
For schizophrenia, memantine has been reported to be consistently effective for negative symptoms only. The manic phase of bipolar di …
Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.
Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Kishi T, et al. J Alzheimers Dis. 2017;60(2):401-425. doi: 10.3233/JAD-170424. J Alzheimers Dis. 2017. PMID: 28922160 Review.
BACKGROUND: The clinical benefit of memantine for Alzheimer's disease (AD) remains inconclusive. OBJECTIVE: We performed an updated systematic review and meta-analysis of the efficacy/safety of memantine in AD. ...Effect size based on a random-effects model was eval …
BACKGROUND: The clinical benefit of memantine for Alzheimer's disease (AD) remains inconclusive. OBJECTIVE: We performed an updated s …
Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder.
Grant JE, Chesivoir E, Valle S, Ehsan D, Chamberlain SR. Grant JE, et al. Am J Psychiatry. 2023 May 1;180(5):348-356. doi: 10.1176/appi.ajp.20220737. Epub 2023 Feb 22. Am J Psychiatry. 2023. PMID: 36856701 Clinical Trial.
To date there is a severe paucity of evidence-based treatments for these conditions. In this study, the authors sought to determine whether memantine, a glutamate modulator, is more effective than placebo in reducing hair-pulling and skin-picking behavior. ...At study endp …
To date there is a severe paucity of evidence-based treatments for these conditions. In this study, the authors sought to determine whether …
Amantadine and memantine: a comprehensive review for acquired brain injury.
Ma HM, Zafonte RD. Ma HM, et al. Brain Inj. 2020 Feb 23;34(3):299-315. doi: 10.1080/02699052.2020.1723697. Epub 2020 Feb 20. Brain Inj. 2020. PMID: 32078407 Review.
This comprehensive review discusses clinical studies of patients following brain injuries (traumatic, acquired, or stroke), who have been treated with amantadine or memantine. Both amantadine and memantine are commonly used in the acute rehabilitation setting follow …
This comprehensive review discusses clinical studies of patients following brain injuries (traumatic, acquired, or stroke), who have been tr …
Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias.
Balázs N, Bereczki D, Kovács T. Balázs N, et al. Ideggyogy Sz. 2021 Nov 30;74(11-12):379-387. doi: 10.18071/isz.74.0379. Ideggyogy Sz. 2021. PMID: 34856086 Free article. Review. English.
Patients' and caregivers' quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available symptomatic treatments. Cholinesterase inhibitors and memantine have been the cornerstones of Alzheimer's therapy for approximately t …
Patients' and caregivers' quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available …
Memantine.
Jarvis B, Figgitt DP. Jarvis B, et al. Drugs Aging. 2003;20(6):465-76; discussion 477-8. doi: 10.2165/00002512-200320060-00005. Drugs Aging. 2003. PMID: 12710865 Review.
Memantine, an uncompetitive antagonist with moderate affinity for NMDA receptors, demonstrates voltage-dependency and relatively fast on/off receptor kinetics. ...Memantine 10 mg/day improved measures of dementia in care-dependent inpatients with Alzheimer's disease …
Memantine, an uncompetitive antagonist with moderate affinity for NMDA receptors, demonstrates voltage-dependency and relatively fast …
Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis.
Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Guo J, et al. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. Brain Behav. 2020. PMID: 32914577 Free PMC article.
CONCLUSIONS: Memantine plus donepezil showed superior outcomes for cognition, global assessment, daily activities, and neuropsychiatric symptoms, but lower acceptability than monotherapy and placebo. Combination therapy may be more cost-effective, because memantine …
CONCLUSIONS: Memantine plus donepezil showed superior outcomes for cognition, global assessment, daily activities, and neuropsychiatr …
Memantine Derivatives as Multitarget Agents in Alzheimer's Disease.
Marotta G, Basagni F, Rosini M, Minarini A. Marotta G, et al. Molecules. 2020 Sep 2;25(17):4005. doi: 10.3390/molecules25174005. Molecules. 2020. PMID: 32887400 Free PMC article. Review.
Memantine (3,5-dimethyladamantan-1-amine) is an orally active, noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist approved for treatment of moderate-to-severe Alzheimer's disease (AD), a neurodegenerative condition characterized by a progressive cognitive decl …
Memantine (3,5-dimethyladamantan-1-amine) is an orally active, noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist approv …
Augmentation With Memantine in Obsessive-Compulsive Disorder.
Andrade C. Andrade C. J Clin Psychiatry. 2019 Dec 3;80(6):19f13163. doi: 10.4088/JCP.19f13163. J Clin Psychiatry. 2019. PMID: 31846244 Free article. Review.
The weighted mean difference between memantine and placebo groups was nearly 8 points on the Yale-Brown Obsessive Compulsive Scale. ...It is concluded that, despite the very large benefits reportedly associated with memantine augmentation, the routine use of mema …
The weighted mean difference between memantine and placebo groups was nearly 8 points on the Yale-Brown Obsessive Compulsive Scale. . …
Memantine for dementia.
Areosa Sastre A, McShane R, Sherriff F. Areosa Sastre A, et al. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003154. doi: 10.1002/14651858.CD003154.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003154. doi: 10.1002/14651858.CD003154.pub3. PMID: 15495043 Updated. Review.
OBJECTIVES: To determine the clinical efficacy and safety of memantine for people with Alzheimer's disease, or vascular or mixed dementia. ...Patients with mild to moderate vascular dementia receiving memantine 20 mg/day had less cognitive deterioration at 28 weeks …
OBJECTIVES: To determine the clinical efficacy and safety of memantine for people with Alzheimer's disease, or vascular or mixed deme …
4,642 results

Searches related to "memantine"